KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer

By afschroeder • June 12, 2025

Luo L, Wang X, Liao YP, Nel AE. KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer. Adv Sci (Weinh). 2025 Jun 11:e04886. doi: 10.1002/advs.202504886. Epub ahead of print. PMID: 40498983.

Tags: cancer immunity cycle, dual drug silicasome, immunotherapy, lipid nanoparticles, mRNA delivery, Nano Medicine, pancreatic cancer, Post Doc, Publications, TLR agonists

Reprogramming the Tolerogenic Immune Response Against Pancreatic Cancer Metastases by Lipid Nanoparticles Delivering a STING Agonist Plus Mutant KRAS mRNA

Xu X, Wang X, Liao YP, Luo L, Nel AE. Reprogramming the Tolerogenic Immune Response Against Pancreatic Cancer Metastases by Lipid Nanoparticles Delivering a STING[...]

Correction: Reduction of pulmonary toxicity of metal oxide nanoparticles by phosphonate-based surface passivation

Cai X, Lee A, Ji Z, Huang C, Chang CH, Wang X, Liao YP, Xia T, Li R. Correction: Reduction of pulmonary toxicity of metal[...]

Role of ESCCAL-1 in regulating exocytosis of AuNPs in human esophageal squamous carcinoma cells

Gong F, Cui Y, Lv P, Liu J, Sun X, Han P, Zhou L, Xia T, Cao W. Role of ESCCAL-1 in regulating exocytosis of[...]